Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Astellas Says Full-Year Profit Rose 16% Vesicare Sales

May 10 (Bloomberg) -- Astellas Pharma Inc., Japan’s third-largest drugmaker, said full-year profit rose 16 percent, led by higher sales of urinary disorder treatment Vesicare.

Net income rose to 78.2 billion yen ($981 million), or 169.4 yen a share, in the 12 months ended March from 67.7 billion yen, or 146.5 yen a share, a year earlier, Tokyo-based Astellas said in a statement today. Profit was expected to rise to 87.6 billion yen, according to the average of 14 analyst estimates compiled by Bloomberg.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at kmatsuyama2@bloomberg.net.

To contact the editor responsible for this story: Jason Gale in Melbourne at j.gale@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.